Related Experiment Video
Updated: Aug 5, 2026

A Murine Model of Vertical Sleeve Gastrectomy
Published on: December 18, 2017
Type I gastric ulcer treated by parietal cell vagotomy and mucosal ulcerectomy
1Department of Surgery, Baylor College of Medicine, Houston, TX, USA.
Background:
Type I gastric ulcers occur at the gastric incisura and do not coexist with duodenal or pyloric ulcers. Antrectomy and Billroth I anastomosis are the most frequent operations used for treatment of patients with this lesion.
Study Design:
Postoperative results, including recurrence, were evaluated in 48 patients with a Type I gastric ulcer who were treated by parietal cell vagotomy and mucosal excision of the ulcer and had a mean follow-up of eight years.
Results:
There was no operative mortality and no major operative complications occurred. The patients have had follow-up examination for a mean of eight years. All but four patients were in Visick I and II categories when last examined. Four patients were in category IV because they required a second gastric operation. The cumulative probability of recurrent ulcer rate calculated by life table analysis was 6.5 plus or minus 9.5 (standard error of the mean) percent at nine years.
Conclusions:
Parietal cell vagotomy and ulcerectomy is an excellent operation for patients with Type I gastric ulcers and provides an alternative to antrectomy for patients with this lesion.
More Related Videos
04:05Endoscopic Vacuum Therapy for the Treatment of Anastomotic Leakage after Total Gastrectomy with Esophagojejunostomy
Published on: August 22, 2025
04:08Evaluation of the Effectiveness of Longitudinal Incision for Endoscopic Submucosal Excavation of Gastric Subepithelial Lesions
Published on: April 28, 2026
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Peptic Ulcer Disease II: Pathophysiology